Acadian Asset Management
LAB icon

Acadian Asset Management’s Standard BioTools LAB Stock Holding History

Acadian Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43K Buy
+53,414
New +$50.5K ﹤0.01% 1866
2024
Q1 		– Sell
-8,868
Closed -$19K – 1686
2023
Q4 		$19K Sell
8,868
-8,742
-50% -$18.7K ﹤0.01% 1593
2023
Q3 		$50K Buy
+17,610
New +$46.1K ﹤0.01% 1431
2021
Q1 		– Sell
-566,314
Closed -$3.4M – 2191
2020
Q4 		$3.4M Buy
566,314
+179,630
+46% +$1.18M 0.01% 608
2020
Q3 		$2.87M Sell
386,684
-945,502
-71% -$6.53M 0.01% 572
2020
Q2 		$5.34M Sell
1,332,186
-208,550
-14% -$726K 0.02% 470
2020
Q1 		$3.91M Sell
1,540,736
-146,945
-9% -$483K 0.02% 443
2019
Q4 		$5.87M Buy
1,687,681
+417,327
+33% +$1.47M 0.03% 407
2019
Q3 		$5.88M Buy
1,270,354
+215,610
+20% +$1.7M 0.03% 439
2019
Q2 		$13M Buy
1,054,744
+208,982
+25% +$2.66M 0.06% 243
2019
Q1 		$11.2M Buy
845,762
+307,013
+57% +$3.24M 0.05% 278
2018
Q4 		$4.64M Buy
538,749
+62,686
+13% +$488K 0.02% 387
2018
Q3 		$3.57M Buy
476,063
+49,972
+12% +$355K 0.01% 439
2018
Q2 		$2.54M Buy
426,091
+124,708
+41% +$711K 0.01% 504
2018
Q1 		$1.76M Buy
301,383
+154,678
+105% +$1.02M 0.01% 613
2017
Q4 		$864K Buy
146,705
+59,839
+69% +$328K ﹤0.01% 715
2017
Q3 		$438K Sell
86,866
-94,521
-52% -$397K ﹤0.01% 805
2017
Q2 		$732K Sell
181,387
-120,318
-40% -$570K ﹤0.01% 756
2017
Q1 		$1.72M Buy
301,705
+95,056
+46% +$602K 0.01% 658
2016
Q4 		$1.5M Sell
206,649
-37,809
-15% -$237K 0.01% 643
2016
Q3 		$1.96M Sell
244,458
-21,532
-8% -$198K 0.01% 551
2016
Q2 		$2.4M Sell
265,990
-161,066
-38% -$1.51M 0.01% 491
2016
Q1 		$3.45M Buy
427,056
+337,583
+377% +$2.43M 0.02% 458
2015
Q4 		$968K Buy
+89,473
New +$879K 0.01% 696

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Acadian Asset Management's LAB Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Standard BioTools (LAB) in Q2 2026: 53,414 shares worth $43K. The stake represents ﹤0.01% of the portfolio and ranks #1866 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in LAB as recently as Q4 2023.

Acadian Asset Management first reported a position in LAB in Q4 2015 and has held it in 24 quarters since. The position peaked at $13M in Q2 2019. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Acadian Asset Management held 53,414 shares of Standard BioTools worth $43K as of Q2 2026.
  • Standard BioTools was a new Acadian Asset Management position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1866 holding.
  • Acadian Asset Management first reported a position in Standard BioTools in Q4 2015 and has held it in 24 quarters since.
  • Acadian Asset Management's Standard BioTools position peaked at $13M in Q2 2019.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.